Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsNasopharyngeal CarcinomaOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU(400/250)/DOCE75/CISP100/FU700, Head and Neck Tumors, C1 (PID1348) -|- CETU250/CISP100/DOCE75/FU700, C2-3 (PID1349)CETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).CISP100/Radiation, Nasopharyngeal Ca, A (PID1714) -|- CISP80/FU1000, Nasopharyngeal Ca, B (PID1707)CRBP100/Radiation, Nasopharyngeal Ca, A (PID1781) -|- CRBP5/FU1000, Nasopharyngeal Ca, B (PID1782)DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750 - CISP40/Radiation, Nasopharyngeal Ca, A (PID1099) -|- B (PID1101)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)PAED CISP100/FU1000, Nasopharyngeal Ca, A (PID723) -|- B (PID682) -|- C (PID738)PAED CRBP500/FU1000, Nasopharyngeal Ca, A (PID681) -|- B (PID682) -|- C (PID738)ChemotherapyChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateNo. Substances1234567811Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseInductionseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAstheniaDiarrheaDysphagiaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaHeadacheHepatotoxicityHypomagnesemiaHyponatremiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMucositisMyositisNail ChangesNauseaNephrotoxicityNeuropathyNeutropeniaOral MucositisOtotoxicityPneumoniaPruritusRadiation DermatitisRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAdelstein DBuehrlen MChitapanarux IFerris RFrikha MFury MHaddad RLee ALee AWMMedina JAPatil VMSamlowski ESuntharalingam MSun YWanebo HYou RZhang LDiseasefortgeschrittenes Nasopharynxkarzinom, T1-4N2-3M0, ECOG 0-2Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-, Erstlinie, ECOG 0-1Lokal fortgeschrittene Kopf-Hals-Tumoren, cT2 oder höher und N2–N3b nach AJCC 1997, ECOG 0-2lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes Nasopharynx-Ca, Tx und N2/N3 oder T3/T4 und Nx, ECOG 0-2Lokal fortgeschrittenes NasopharynxkarzinomLokal fortgeschrittenes Nasopharynxkarzinom Metastasiertes Nasopharynxkarzinom, CR oder PR nach 3 Zyklen Chemotherapie mit Cisplatin/5-FU, ECOG 0-2Nasopharynx-Ca, Stadium III-IVb, ECOG0-2Nasopharynxkarzinom, Stadium I - IV, unter 25 JahreNasopharynxkarzinom, Stadium III - IV, unter 25 JahreNasopharynxkarzinom, Stadium III- IV, unter 25 JahreNasopharynxkarzinom, Stadium III-IVB, Erstlinieneudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1rezidivierende oder metastasierte Kopf-Hals-Tumoren, Zweitlinie, ECOG 0-2rezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2wiederkehrender oder metastasierter Kopf-Hals-Tumor nach Platintherapiewiederkehrendes oder metastasiertes Nasopharynxkarzinom, nach Radiatio, ECOG 0-1OriginCancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of ChinaChiang Mai University, Chiang Mai, ThailandCleveland Clinic Foundation, ClevelandDepartment of Clinical Oncology, The University of Hong Kong, NPC‐0501 trialDepartment of Medical Oncology, Dana Farber Cancer Institute, BostonDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New YorkDepartment of Pediatric and Adolescent Medicine, University Hospital Aachen, Germany, NPC-2003-GPOH/DCOGDepartment of Radiation Oncology, Sun Yatsen University Cancer Centre, ChinaDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Head and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsMedical Oncology department, University Hospital, Sfax (Tunisia), GORTEC 2006-02NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupOhio State University Comprehensive Cancer Center, Ohio State University, ColumbusServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainSun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ChinaTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversity of Utah Health Science Center, Salt Lake City, Utah, A Southwest Oncology GroupProtocols in Revision 26 protocols foundProtocols under revision.Carboplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1781 V1.0)Carboplatin 5 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1782 V1.0)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348 V1.3)Cetuximab 250 / Cisplatin 100 / Docetaxel 75 / Fluorouracil 700, Head and Neck Tumors, Cycle 2-3 (PID1349 V1.3)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244 V1.1)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621 V1.1)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622 V1.1)Cetuximab 500, Head and Neck Tumors (PID1241 V1.1)Cisplatin 100 / Capecitabine 1000, Nasopharyngeal Carcinoma (PID1784 V1.2)Cisplatin 100 / Fluorouracil 1000 / Radiation, Nasopharyngeal Carcinoma (PID1737 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334 V1.1)Cisplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1714 V1.1)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637 V1.1)Cisplatin 80 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1707 V1.1)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259 V1.0)Docetaxel 60 / Cisplatin 60 / Fluorouracil 600, Nasopharyngeal Carcinoma (PID1373 V1.1)Docetaxel 65 / Carboplatin 6, Head and Neck Tumors (PID1278 V1.0)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1099 V1.1)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part B (PID1101 V1.1)Gemcitabine 1000 / Cisplatin 80, Nasopharyngeal Carcinoma (PID1325 V1.1)Nivolumab 240, Head and Neck Tumors (PID856 V2.0)Oxaliplatin 70 / Radiation, Nasopharyngeal Carcinoma (PID1783 V1.0)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295 V1.1)PAED Carboplatin 500 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID681 V1.0)PAED Cisplatin 100 / Folinic Acid 25 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID723 V1.1)PAED Cisplatin 20 / Radiation, Nasopharyngeal Carcinoma, Part B (PID682 V1.0)
